Lilly weight-loss drug copycats dealt blow as shortage ends
By Ike Swetlitz and Madison Muller, Bloomberg News Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines. The Food and Drug Administration said Wednesday that the shortage of Lilly’s Zepbound and…